Cardiogen

Cardiogen Molecular Structure & Chemical Properties

Cardiogen represents a distinctive class of peptide bioregulators—short amino acid sequences designed to modulate cellular function at the genetic level. Developed in the 1980s-1990s by researchers at the St. Petersburg Institute of Bioregulation and Gerontology, this synthetic tetrapeptide has generated substantial research interest for its tissue-specific regulatory properties, particularly in cardiovascular and oncology models. Unlike conventional pharmacological agents that target single receptors, Cardiogen’s four-amino acid structure enables it to influence multiple cellular pathways simultaneously, including gene expression, protein synthesis, and apoptosis regulation. The peptide’s small molecular size facilitates cellular uptake and potentially allows nuclear translocation, characteristics that distinguish it from larger protein-based therapeutics.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The tetrapeptide structure contains two acidic residues (glutamic acid and aspartic acid) flanked by alanine and arginine, creating a charged molecule that may facilitate interactions with cellular membranes and nuclear components. This precise sequence appears critical for bioregulatory activity, as demonstrated in comparative studies with related peptides.

Cardiogen Mechanism of Action

Cardiogen peptide exerts its biological effects through tissue-specific gene regulation rather than classical receptor-mediated signaling. Current research suggests the peptide functions as a genetic bioregulator, directly influencing transcription factor activity and gene expression patterns in target cells. This mechanism distinguishes it from hormone mimetics or growth factors, positioning it as a coordinator of cellular repair programs rather than a direct stimulator of single pathways.

Primary Cellular Pathways

Gene Expression Modulation – Transcriptional Regulation

Research demonstrates that Cardiogen can penetrate cellular membranes and localize to the nucleus, where it influences DNA-associated proteins and transcription factors. Studies using mouse embryonic fibroblasts showed:

• Significant upregulation of cytoskeletal protein expression (actin, vimentin, tubulin increased 2-5 fold)
• Enhanced nuclear matrix protein synthesis (lamin A and C increased 2-3 fold)
• Modulation of gene accessibility for transcription through chromatin remodeling
• Activation of intracellular metabolic pathways supporting proliferation and differentiation

This transcriptional activity suggests Cardiogen peptide functions as an epigenetic modifier, altering which genes are available for expression without changing the DNA sequence itself.

p53 Pathway Suppression – Antiapoptotic Effects in Cardiac Tissue

Cardiogen has been observed to reduce expression of p53 protein, often called the “guardian of the genome,” in cardiac tissues. This mechanism appears to:

• Decrease apoptosis rates in cardiomyocytes under stress conditions
• Promote cell survival during ischemic injury
• Support proliferation of cardiac progenitor cells
• Enable tissue remodeling without excessive cell death

The downregulation of p53 in heart tissue may contribute to improved outcomes in cardiac remodeling scenarios, potentially reducing progression to heart failure.

Fibroblast Activity Regulation – Extracellular Matrix Modulation

The peptide demonstrates significant effects on fibroblast behavior, the primary cells responsible for tissue repair and scar formation:

• Stimulation of collagen and elastin synthesis in repair contexts
• Modulation of extracellular matrix component secretion
• Influence on fibroblast signaling factor expression
• Potential normalization of age-related fibroblast dysfunction

Research indicates this dual regulation—supporting beneficial fibroblast activity while limiting excessive scar formation—represents a key mechanism for tissue repair applications.

Vascular Network Effects – Tumor-Selective Action

Emerging evidence suggests Cardiogen may exert selective effects based on tissue vascular characteristics:

• Differential apoptosis induction in tumor versus normal tissue
• Potential targeting through abnormal tumor vasculature
• Hemorrhagic necrosis development in tumor models
• Vascular-mediated delivery of bioregulatory signals

This vascular selectivity may explain the peptide’s contrasting effects—antiapoptotic in normal cardiac tissue but proapoptotic in certain tumor types.

Cytoskeletal Protein Enhancement – Structural Support

Investigation of Cardiogen’s effects on structural proteins revealed:

• Enhanced synthesis of actin, vimentin, and tubulin
• Improved cellular scaffolding and mechanical stability
• Support for cell migration and tissue remodeling
• Maintenance of cellular architecture under stress

These structural protein effects may contribute to the peptide’s observed benefits in tissue repair and regeneration models.

Cardiogen Research Applications & Key Findings

Cardiovascular Research

Cardiac Tissue Repair and Remodeling

Extensive research in rodent models has examined Cardiogen’s effects on cardiac tissue following injury. Studies in organotypic myocardial tissue cultures from young and aged rats demonstrated:

• Stimulation of cardiomyocyte proliferation in both young and aged tissue (concentration: 10^-12 M)
• Decreased p53 protein expression correlating with reduced apoptosis
• Seven amino acids showed proliferative effects in young rats, but only two in aged rats
• Cardiogen demonstrated robust stimulatory effects regardless of tissue age

In myocardial infarction models, investigations revealed that Cardiogen peptide administration resulted in:

• Reduced necrotic zone formation following coronary artery ligation
• Preservation of myocardial glycogen stores (energy reserves)
• Protection of mitochondrial integrity
• Enhanced reparative processes and improved cardiomyocyte metabolism

Fibrosis Reduction and Scar Limitation

Research suggests Cardiogen may favorably alter cardiac remodeling by:

• Promoting cardiomyocyte proliferation while inhibiting fibroblast overactivity
• Reducing scar tissue formation in injury models
• Improving long-term outcomes in scenarios leading toward congestive heart failure
• Supporting more organized collagen deposition versus disorganized scarring

The dual effect—supporting necessary repair while limiting pathological fibrosis—represents a unique characteristic among investigated peptide bioregulators.

Oncology Research

Tumor Apoptosis Studies – M-1 Sarcoma Models

Groundbreaking research by Levdik and Knyazkin at the St. Petersburg Institute of Bioregulation and Gerontology examined Cardiogen in rat sarcoma models:

• Dose-dependent tumor growth inhibition in M-1 sarcoma transplant models
• Significantly elevated apoptosis levels in tumor cells compared to controls
• Development of hemorrhagic necrosis within tumor tissue
• Effect mediated through tumor vascular network rather than direct cytostatic action

The concentration-dependent nature of these effects suggests genuine biological activity rather than non-specific toxicity.

Prostate Cancer Signaling Research

In vitro investigations examined Cardiogen’s effects on prostate fibroblast signaling:

• Modulation of signaling factors that create tumor-favorable microenvironments
• Normalization of age-related changes in fibroblast signaling molecule expression
• Potential restoration to levels comparable with young, healthy fibroblasts
• Relevance to age-associated cancer progression mechanisms

These findings suggest potential applications in age-related cancer prevention research, though human validation remains absent.

Cellular Biology Research

DNA Interaction and Protection

Studies using HeLa cells and other models indicated that Cardiogen:

• Penetrates cytoplasm, nucleus, and nucleolus
• Inhibits endonuclease-catalyzed DNA hydrolysis
• May interact with enzymes rather than binding DNA directly
• Potentially protects genetic material from degradation

Protein Synthesis Regulation

Investigations in knockout LMNA mice (embryonic fibroblasts) showed:

• 2-5 fold increase in cytoplasmic protein expression (actin, vimentin, tubulin)
• 2-3 fold increase in nuclear matrix proteins (lamin A and C)
• Activation of transcription factors and DNA-associated proteins
• Enhanced gene accessibility for cytoskeletal protein encoding

Cardiogen Pharmacokinetics & Metabolism

Absorption & Distribution

Pharmacokinetic characterization of Cardiogen remains limited in published literature, with most data derived from tissue distribution studies rather than formal PK analyses. Available research indicates:

• Rapid cellular uptake following administration in rodent models
• Demonstrated penetration into cytoplasm and nuclear compartments
• Tissue-specific accumulation patterns not extensively characterized
• Multiple administration routes examined (intraperitoneal, subcutaneous, oral in some protocols)

The peptide’s small molecular size and specific amino acid composition may facilitate membrane crossing, though the exact transport mechanisms—whether passive diffusion, carrier-mediated, or receptor-facilitated—remain under investigation.

Metabolism & Elimination

The metabolic fate of Cardiogen has not been comprehensively defined in peer-reviewed publications. General principles for small peptides suggest:

• Likely degradation by peptidases in plasma and tissues
• Potential rapid clearance typical of short, unmodified peptides
• Specific metabolites and their activities not characterized
• Enzymatic breakdown pathways require elucidation

The apparent persistence of biological effects beyond what would be expected for a rapidly cleared peptide suggests either tissue retention, active metabolites, or long-lasting changes in gene expression triggered by transient peptide exposure.

Excretion Pathways

Limited published data addresses Cardiogen elimination routes. Based on peptide pharmacology principles:

• Renal excretion likely plays a role for peptide fragments
• Hepatic metabolism may contribute to clearance
• No accumulation reported in chronic dosing studies (animal models)
• Formal excretion kinetics studies not available in literature

The disconnect between presumed rapid clearance and sustained biological effects represents a significant pharmacokinetic question requiring systematic investigation.

Cardiogen Research Protocols & Administration

Dosing in Published Research

Published investigations have employed varied Cardiogen concentrations and doses depending on model system:

• Tissue culture studies: 10^-12 M concentration for organotypic myocardial cultures
• Rat sarcoma models: Dose-dependent effects observed (specific doses not consistently reported across studies)
• In vitro cell studies: Typically 30-minute incubation periods at experimental concentrations
• General range: Investigations span picomolar to micromolar concentrations depending on application

Important: These are experimental concentrations and doses used in laboratory research models and cannot be extrapolated to other species due to fundamental differences in metabolism, receptor expression profiles, peptide degradation rates, and pharmacokinetic parameters. Species-specific factors profoundly influence both efficacy and safety characteristics.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical models:

• Intraperitoneal injection – Commonly used in rodent studies for systemic delivery
• Subcutaneous injection – Employed in some chronic administration protocols
• Direct tissue application – Used in cell culture and ex vivo tissue studies
• Intravenous administration – Applied in select pharmacokinetic characterization studies

Route selection in published research typically depends on the experimental model and research objectives rather than optimization for bioavailability.

Common Model Organisms

Cardiogen research has utilized various experimental systems:

• Rats – Primary model for cardiovascular and tumor studies (Wistar, senescent rat strains)
• Mice – Employed in genetic models (LMNA knockout, transgenic lines)
• Cell culture systems – HeLa cells, embryonic fibroblasts, cardiac tissue explants, prostate fibroblasts
• Organotypic cultures – Myocardial tissue from young (3-month) and aged (24-month) rats

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite decades of investigation since its development in the 1980s-1990s, Cardiogen faces substantial translational barriers that severely limit scientific interpretation and preclude any clinical consideration.

Absence of Human Clinical Data

The most significant limitation is the complete lack of human research:

• No peer-reviewed human clinical trials exist in scientific databases
• No Phase I, II, or III studies published or registered
• Human safety profile entirely unestablished
• Optimal human dosing unknown and cannot be extrapolated from animal data
• Long-term effects in humans completely unstudied
• No data on human pharmacokinetics, bioavailability, or tissue distribution

Mechanistic Understanding Deficits

Fundamental aspects of Cardiogen’s mechanism remain poorly defined:

• Precise molecular targets (receptors, transporters, or binding proteins) not definitively identified
• Gene regulatory mechanisms incompletely characterized
• Relationship between structural changes (protein expression) and functional outcomes unclear
• Tissue selectivity basis not fully elucidated
• Contribution of parent peptide versus potential metabolites unknown
• Signaling cascade sequences require comprehensive mapping

Long-Term Safety Unknowns

Critical safety questions remain unanswered even in animal models:

• Chronic administration effects beyond weeks to months unstudied
• Potential for uncontrolled cell proliferation with extended use not assessed
• Effects on cancer development or progression inadequately investigated
• Reproductive and developmental toxicity not systematically evaluated
• Drug interaction potential completely uncharacterized
• Immune system effects with repeated administration not defined

Publication and Validation Gaps

Research quality considerations include:

• Most studies originate from a limited number of research groups
• Independent replication of findings across laboratories limited
• Standardized protocols for peptide administration and outcome assessment lacking
• Publication bias toward positive findings likely present
• Mechanistic studies often descriptive rather than hypothesis-driven

Regulatory & Competitive Sport Status

FDA Position

Cardiogen has not received approval from the U.S. Food and Drug Administration:

• Not approved for any human or veterinary indication
• Not recognized as Generally Recognized as Safe (GRAS)
• No established basis for therapeutic use
• Not legally available for compounding in the United States
• No regulatory pathway currently established

The FDA has not issued specific guidance documents on Cardiogen, but peptide bioregulators generally fall under unapproved drug substance classifications.

International Regulatory Status

• Developed in Russia but regulatory approval status unclear even in country of origin
• Not approved by European Medicines Agency (EMA)
• No marketing authorizations in any jurisdiction confirmed in scientific literature
• Availability limited to research chemical suppliers

WADA Prohibition

World Anti-Doping Agency classification not specifically documented for Cardiogen in publicly available prohibited substance lists. However:

• Peptide bioregulators generally fall under prohibited substance categories
• No therapeutic use exemptions would be available absent regulatory approval
• Use in competitive athletics would likely violate anti-doping regulations

Research Classification: Cardiogen is available exclusively for laboratory research purposes. It is not intended for human consumption, medical applications, or veterinary use. All research must be conducted under appropriate ethical oversight with institutional review board approval where applicable and in compliance with applicable regulations governing research chemical use.

References

1. Chalisova NI, Lesniak VV, Balykina NA, Urt’eva SA, Urt’eva TA, Sukhonos IuA, Zhekalov AN. [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]. Adv Gerontol. 2009;22(3):409-13. Russian. PMID: 20210190. PubMed
   
2. Levdik NV, Knyazkin IV. Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bull Exp Biol Med. 2009 Sep;148(3):433-6. doi: 10.1007/s10517-010-0730-9. PMID: 20396706. PubMed
   
3. Khavinson VKh, Fedoreyeva LI, Vanyushin BF. Site-specific binding of short peptides with DNA modulated eukaryotic endonuclease activity. Bull Exp Biol Med. 2011 May;151(1):66-70. doi: 10.1134/S0006297911070036. PMID: 22808482. PubMed
   
4. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021 Nov 22;26(22):7053. doi: 10.3390/molecules26227053. PMID: 34834147; PMCID: PMC8619776. PubMed
   
5. Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell. 2005 Dec;4(6):291-8. doi: 10.1111/j.1474-9726.2005.00173.x. PMID: 16300481. PubMed
   
6. Kheifets OV, Poliakova VO, Kvetnoi IM. [Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging]. Adv Gerontol. 2010;23(1):68-70. Russian. PMID: 20586252. PubMed
   

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Cardiogen is intended for laboratory research use only.